Electronic System Reminds Patients to Schedule Exams

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 4
Volume 16
Issue 4

A computerized mail and phone reminder program managed by appointment secretaries significantly increased the percentage of patients undergoing annual mammography at the Mayo Clinic

ROCHESTER, Minnesota—A computerized mail and phone reminder program managed by appointment secretaries significantly increased the percentage of patients undergoing annual mammography at the Mayo Clinic, according to a study by Rajeev Chaudhry, MBBS, MPH, and colleagues (Arch Intern Med 167:606-611, 2007).

The researchers randomized 6,665 women age 40 to 75 to usual care or to an intervention group that received mailings (two monthly letters starting 3 months before they were due for screening) followed by a phone call to nonresponding patients, to remind them to schedule a mammogram.

Among the reminded group, 64.3% had their annual mammogram vs 55.3% of controls (P < .001). There were no significant differences between the two groups for any of the other adult preventive services. A subgroup that also received an email reminder had a 72.2% compliance rate. As the program has expanded following the study period, compliance has now grown to more than 72%, Dr. Chaudhry said, with 86% having had one exam within the previous 2 years.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content